$143 Million is the total value of Foresite Capital Management V, LLC's 14 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 17.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Pardes Biosciences Inc | $28,860,000 | -57.5% | 9,400,515 | 0.0% | 20.16% | -27.3% | ||
| Buy | Theseus Pharmaceuticals, Inc. | $18,444,000 | -50.2% | 3,335,346 | +3.8% | 12.88% | -14.8% | |
| ACRS | Aclaris Therapeutics, Inc. | $17,565,000 | -19.0% | 1,258,243 | 0.0% | 12.27% | +38.5% | |
| Sell | Somalogic, Inc. | $15,894,000 | -46.8% | 3,516,472 | -5.6% | 11.10% | -9.0% | |
| HIMS | Buy | Hims & Hers Health, Inc. | $15,039,000 | +4.2% | 3,319,786 | +22.6% | 10.51% | +78.3% |
| CMPX | Compass Therapeutics, Inc. | $11,660,000 | +93.4% | 4,400,000 | 0.0% | 8.15% | +230.9% | |
| KNTE | Kinnate Biopharma Inc. | $11,034,000 | +12.0% | 875,001 | 0.0% | 7.71% | +91.6% | |
| ACET | Adicet Bio, Inc. | $9,928,000 | -26.9% | 680,000 | 0.0% | 6.94% | +25.1% | |
| Adagio Therapeutics, Inc. | $4,696,000 | -28.1% | 1,431,826 | 0.0% | 3.28% | +23.1% | ||
| GMTX | Gemini Therapeutics, Inc. | $4,115,000 | +21.6% | 2,435,125 | 0.0% | 2.88% | +108.0% | |
| QSI | Sell | Quantum-Si Incorporated | $2,145,000 | -80.4% | 924,379 | -60.5% | 1.50% | -66.5% |
| ENTA | Enanta Pharmaceuticals, Inc. | $1,997,000 | -33.6% | 42,250 | 0.0% | 1.40% | +13.6% | |
| ME | 23andMe Holding Co. | $1,009,000 | -35.2% | 406,913 | 0.0% | 0.70% | +10.8% | |
| PHVS | Pharvaris N.V. | $755,000 | +22.0% | 34,142 | 0.0% | 0.53% | +108.3% | |
| Exit | Cue Health Inc. | $0 | – | -490,546 | -100.0% | -1.29% | – | |
| RACB | Exit | Research Alliance Corp. II | $0 | – | -500,000 | -100.0% | -1.99% | – |
| CGEM | Exit | Cullinan Oncology, Inc. | $0 | – | -992,507 | -100.0% | -4.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.